Simponi approved for ulcerative colitis

(HealthDay)—Simponi (golimumab) injection has been approved by the U.S. Food and Drug Administration to treat adults with moderate-to-severe ulcerative colitis.

The drug is designed to block , which has a key role in causing abnormal inflammation and , the FDA said Wednesday in a news release.

The drug has already been approved to treat psoriatic arthritis, rheumatoid arthritis and , the agency said.

Ulcerative colitis, affecting some 620,000 Americans, causes chronic inflammation and ulcers in the inner lining of the large intestine. Common symptoms include abdominal discomfort, gastrointestinal bleeding and diarrhea.

Simponi was clinically evaluated in two studies involving more than 800 people. The most common side effects reported were upper respiratory infection and redness at the injection site. People treated with the drug are at greater-than-average risk of contracting several types of infection, lymphoma, heart failure, nervous system disorders and allergic reactions, the FDA said.

The drug is marketed by Janssen Ortho Biotech Inc., based in Horsham, Pa.

More information: Medline Plus has more about ulcerative colitis.

add to favorites email to friend print save as pdf

Related Stories

Xeljanz approved for rheumatoid arthritis

Nov 07, 2012

(HealthDay)—Xeljanz (tofacitinib) has been approved by the U.S. Food and Drug Administration to treat symptoms of rheumatoid arthritis (RA) among people who can't tolerate, or haven't been helped by, the drug methotrexate.

FDA approves Procysbi for nephropathic cystinosis

May 02, 2013

(HealthDay)—Procysbi (cysteamine bitartrate) delayed-release capsules have been approved by the U.S. Food and Drug Administration to treat nephropathic cystinosis in children (6 years and up) and adults. ...

Gattex approved for short bowel syndrome

Dec 22, 2012

(HealthDay)—Gattex (teduglutide) has been approved by the U.S. Food and Drug Administration to treat nutritional problems caused by short bowel syndrome.

Recommended for you

EU regulator: Morning-after pill OK for all women

10 hours ago

(AP)—A commonly used morning-after pill is suitable for use by heavier women, the European Medicines Agency said Thursday after a review of the evidence sparked by the French manufacturer's declaration that the drugs didn't ...

Physicians warned about counterfeit medical devices

15 hours ago

(HealthDay)—Physicians should be aware of the prevalence and serious consequences associated with use of counterfeit medical devices, according to a letter to the editor published online July 20 in Lasers in ...

Zydelig approved for three types of blood cancer

15 hours ago

(HealthDay)—Zydelig (idelalisib) has been approved by the U.S. Food and Drug Administration to treat relapsed forms of blood cancer, including chronic lymphocytic leukemia (CLL), follicular B-cell non-Hodgkin lymphoma (FL) ...

Journal raises concern about blood-thinning drug

Jul 23, 2014

A medical journal raised concerns Wednesday about a blood-thinning drug widely used by people at risk of stroke, accusing its manufacturer of concealing safety data and regulators of laxness.

User comments